Azeptin® was administered to 48 patients with perennial allergic rhinitis for prolonged periods to determine its efficacy and safety.
1) The rate of improvement, as determined by a final general improvement rating, was 60.5% when “moderately improved” or better evaluations were included. The rate of usefulness was 66.0% when “moderately or more useful” evaluations were included.
2) The rate of improvement, as determined by a general improvement rating for subjective symptoms, was 61.4% when “moderately improved” or better evaluations were included. The rate of disappearance was high for sneezing (82.2%), nasal discharge (66.7%), and nasal obstruction (46.7%).
3) The rate of improvement, as determined by a general improvement rating for objective symptoms, was 56.8% when “moderately improved” or better evaluations were included.
4) The side effect elicited in this study was mild sleepiness which was experienced by one patient. This symptom disappeared without any particular procedure, although the drug was continued.
In conclusion, Azeptin®, even when administered for extended periods of time, can maintain its beneficial effect on perennial allergic rhinitis, with safety as evidenced by only mild side effects. It is concluded that Azeptin® is a very useful drug.